Compare Sanofi SA (SNY) vs Under Armour Inc Class A (UAA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Under Armour Inc Class A — how do they compare? Sanofi SA trades at $43.12 (market cap $103.41B), while Under Armour Inc Class A trades at $5.07 (market cap $2.08B). The key difference: Sanofi SA is far larger — about 49.7× Under Armour Inc Class A's market cap, and Sanofi SA pays a 5.65% dividend while Under Armour Inc Class A pays none. Which is the better fit depends on your goals.
| SNY | UAA | |
|---|---|---|
Market Cap | $103.41B | $2.08B |
Sector | Health | Consumer Cyclical |
52-Week High | $52.34 | $8.14 |
52-Week Low | $41.33 | $4.17 |
Enterprise Value | $123.44B | $3.06B |
Dividend Yield | 5.65% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNY trades at $43.16, down 2.45% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported Q2 2026 EPS of $1.21, beating expectations, and raised its 2026 outlook driven by Dupixent strength. Financials show improved net income of $7.81B in 2025, with a P/E of 22.94 and net margin of 8.09%.
Outlook is mixed: strong drug performance and analyst hold ratings suggest stability, but pipeline setbacks and projected 2026 profit margin decline to 8.09% pose risks. The stock offers a 5.4% dividend yield, trading below sector P/E, presenting value if growth execution offsets challenges.
Under Armour (UAA) trades at $5.06, down 3.62% on the day, reflecting persistent investor concerns. The stock is technically bearish, with moving averages signaling a downtrend. Fundamentally, the company reported a net loss of $201.27 million in 2025, with revenue declining to $5.16 billion. Recent news highlights a reduced revenue outlook for fiscal 2027, though cost discipline aims to preserve profitability.
The outlook remains challenging due to weak North American demand and falling revenue projections. Analyst consensus is a 'Hold' with a $6.67 price target, indicating cautious optimism for margin recovery. Key risks include sustained sales weakness and high debt levels. The stock offers potential upside if margin improvements materialize, but near-term headwinds dominate.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Under Armour Inc Class A
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →
